Stock Market Reviews

Read and share opinions on TMO (Thermo Fisher Scientific Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock ma

Latest News

• BofA Raises Thermo Fisher (TMO) Target as Biopharma Recovery Comes Into View
  Dec 30, 2025
• Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, January 29, 2026
  Dec 26, 2025
• Thermo Fisher Scientific Insiders Sold US$3.6m Of Shares Suggesting Hesitancy
  Dec 23, 2025
• Q3 Earnings Highlights: Thermo Fisher (NYSE:TMO) Vs The Rest Of The Research Tools & Consumables Stocks
  Dec 22, 2025
• Analysts See 12% Upside To Thermo Fisher Scientific Inc. (TMO)
  Dec 20, 2025

TMO News

• What to Expect From Thermo Fisher Scientific's Next Quarterly Earnings Report
  Thermo Fisher Scientific will release its fourth-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.
  Dec 30, 2025
• 3 Low-Volatility Stocks That Fall Short
  A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
  Dec 29, 2025
• What Makes Thermo Fisher (TMO) a Good Investment Choice?
  Artisan Partners, an investment management company, released its “Artisan Value Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The equity market rally persisted in the third quarter as investors ignored tariffs, buoyed by strong corporate earnings, rising AI investment, and prospects of economic support from US fiscal policy and […]
  Dec 29, 2025
• Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, January 29, 2026
  WALTHAM, Mass., December 26, 2025--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2025 before the market opens on Thursday, January 29, 2026, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations.
  Dec 26, 2025
• Sector Rotation: 2 Smart Money Moves for 2026
  Investors are rotating capital into communication services and healthcare stocks as falling interest rates create new opportunities for growth and income.
  Dec 26, 2025
• 2 S&P 500 Stocks Worth Investigating and 1 We Avoid
  While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
  Dec 24, 2025
• Thermo Fisher Scientific Insiders Sold US$3.6m Of Shares Suggesting Hesitancy
  In the last year, many Thermo Fisher Scientific Inc. ( NYSE:TMO ) insiders sold a substantial stake in the company...
  Dec 23, 2025
• Favorable Results and Improved Guidance Lifted Thermo Fisher Scientific (TMO) in Q3
  Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 Index surged in the third quarter, driven by investor optimism that grew on expectations of monetary easing, strong consumer demand, and solid corporate earnings. The Fund (Investor […]
  Dec 23, 2025
• TMO Stock May Benefit From PPD CorEvitas Alzheimer's Registry Launch
  Thermo Fisher launches a global PPD CorEvitas Alzheimer's registry, enrolling its first patient to generate real-world safety and effectiveness data.
  Dec 22, 2025
• Beat the Market the Zacks Way: Micron, Credo, Coca Cola in Focus
  Micron, Credo and Coca-Cola headline Zacks' latest wins, with select portfolios and focus lists posting sharp gains despite a mixed market week.
  Dec 22, 2025
• Q3 Earnings Highlights: Thermo Fisher (NYSE:TMO) Vs The Rest Of The Research Tools & Consumables Stocks
  As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the research tools & consumables industry, including Thermo Fisher (NYSE:TMO) and its peers.
  Dec 22, 2025
• The Zacks Analyst Blog Highlights Walmart, Wells Fargo, Thermo Fisher Scientific, Seneca Foods and NetSol Technologies
  Walmart, Wells Fargo and Thermo Fisher anchor Zacks' latest Analyst Blog as strong execution and innovation drive outperformance.
  Dec 22, 2025
• Analysts See 12% Upside To Thermo Fisher Scientific Inc. (TMO)
  Thermo Fisher Scientific Inc. (NYSE:TMO) is among the 14 Best S&P 500 Stocks to Buy Now. As of the close of business on December 17, Wall Street analysts have a consensus Strong Buy rating on the stock, with a one-year average share price target of $640.30, representing an upside of 12%. Recent analyst updates include Wells […]
  Dec 20, 2025
• 3 Mega-Cap Stocks with Warning Signs
  Megacap stocks dominate their sectors and their actions influence economies worldwide. The flip side though is that their sheer size means they have less room for explosive growth as scale works against them.
  Dec 19, 2025
• Top Stock Reports for Walmart, Wells Fargo & Thermo Fisher Scientific
  Walmart's omnichannel execution, strong comps and expanding higher-margin businesses are driving outperformance despite cost pressures and tariff risks.
  Dec 19, 2025
• How Investors May Respond To Thermo Fisher Scientific (TMO) Expanding Alzheimer’s Registry And Bioprocessing Tools
  Earlier this week, Thermo Fisher Scientific reported the first patient enrollment in its new international PPD CorEvitas Alzheimer’s Disease Registry and introduced next-generation Gibco Bacto CD Supreme media and feed to support higher-yield, chemically defined E. coli–based production of plasmid DNA and recombinant proteins. Together, these moves deepen Thermo Fisher’s role in real-world Alzheimer’s evidence generation while reinforcing its tools franchise in gene therapy and mRNA...
  Dec 19, 2025
• Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer’s Disease Registry to Advance Real-World Evidence in Neurodegenerative Care
  WALTHAM, Mass., December 18, 2025--Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer’s Disease Registry to Advance Real-World Evidence in Neurodegenerative Care.
  Dec 18, 2025
• North America Poised for Highest Growth in Microplastic Analysis Market with 8.5% CAGR
  The global microplastic analysis market is set to grow from USD 266.9 million in 2025 to USD 383.1 million by 2030 at a CAGR of 7.5%. Growth is driven by increased research funding, rising proteomics research, and heightened awareness of microplastic pollution risks. The instruments segment will dominate the market in 2025, with substantial demand for reagents and consumables fueled by regulatory pressures. The water testing segment is experiencing rapid growth due to stricter water quality regu
  Dec 17, 2025
• TMO Stock Set to Gain From the Expansion of Gibco Bacto Portfolio
  Thermo Fisher expands its Gibco Bacto CD portfolio with new formulations aimed at boosting E. coli-based plasmid DNA and protein production efficiency.
  Dec 16, 2025
• 3 Profitable Stocks Walking a Fine Line
  Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
  Dec 15, 2025
• Thermo Fisher Scientific Expands Gibco™ Bacto™ Portfolio with Next-Generation, Chemically Defined Media to Boost E. coli Biomanufacturing Productivity
  WALTHAM, Mass., December 15, 2025--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of Gibco™ Bacto™ CD Supreme FPM Plus and Gibco™ Bacto™ CD Supreme Feed (2X), two next-generation chemically-defined formulations that expand the Gibco™ Bacto™ CD portfolio to enhance and simplify plasmid DNA and recombinant protein production using Escherichia coli (E. coli).
  Dec 15, 2025
• OlivePoint Capital Acquires 3900 Paramount Parkway in Raleigh–Durham, Expanding Its High-Conviction Office Special Situations Strategy
  LOS ANGELES, December 15, 2025--OlivePoint acquires a Class A Raleigh office 100% leased to PPD/Thermo Fisher, highlighting its strategy to target mispriced, credit-backed assets.
  Dec 15, 2025
• Taking Stock of Thermo Fisher Scientific (TMO) Valuation After Analyst Upgrades and Bioprocessing, Cardio Testing Moves
  Thermo Fisher Scientific (TMO) just picked up fresh buy ratings on the back of its Asian bioprocessing expansion and a new cardiovascular risk testing partnership, and investors are treating that combination as a meaningful confidence signal. See our latest analysis for Thermo Fisher Scientific. Although Thermo Fisher’s share price is slightly softer in the very short term, a roughly 21 percent 90 day share price return suggests momentum is rebuilding as investors reprice its Asia buildout...
  Dec 14, 2025
• Becton Dickinson, Bio-Rad, and Thermo Fisher Propel Safety and Automation in Blood Collection Tubes—New Market Report Highlights $7Billion Opportunity
  The blood collection tubes market presents opportunities through innovation in automated systems, advanced materials, and digital traceability to enhance workflow efficiency and compliance. Demand is driven by personalized medicine, diagnostic volume growth, and regulatory needs, with a focus on agility and regional adaptation. Blood Collection Tubes Market Blood Collection Tubes Market Dublin, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The "Blood Collection Tubes Market - Global Forecast 2025-2032" has
  Dec 12, 2025
• Morgan Stanley Analyst Is Bullish On Thermo Fisher Scientific Inc. (TMO)
  Thermo Fisher Scientific Inc. (NYSE:TMO) is among the 13 Best Nanotechnology Stocks to Buy Now. According to The Fly, on December 2, 2025, Morgan Stanley analyst Kallum Titchmarsh established a price objective of $670, up from $656. He initiated coverage of Thermo Fisher Scientific Inc. (NYSE:TMO) with an Overweight rating. According to Titchmarsh, the end […]
  Dec 12, 2025
• Autoimmune Disease Diagnosis Market to Surge to USD 8.98 Billion by 2031
  The autoimmune disease diagnosis market is poised to grow from USD 5.57 billion in 2025 to USD 8.98 billion by 2031, exhibiting a CAGR of 8.3%. Key growth drivers include rising autoimmune disorder prevalence, increased awareness of early detection, and technological advances. Systemic autoimmune diseases lead in market share due to conditions like rheumatoid arthritis and lupus necessitating complex diagnostics. The Asia Pacific region is the fastest-growing, driven by healthcare advancements.
  Dec 12, 2025
• PayPal downgraded, Roku upgraded: Wall Street's top analyst calls
  PayPal downgraded, Roku upgraded: Wall Street's top analyst calls
  Dec 11, 2025
• Is Thermo Fisher Still Attractively Priced After Recent Share Price Dip In 2025?
  Wondering if Thermo Fisher Scientific is still a smart buy at today’s price, or if most of the upside has already been captured? Let us unpack what the market might be missing in the valuation. The stock is up 7.8% year to date and 5.5% over the last 12 months, even after a recent 3.0% dip in the past week and a modest 1.6% slide over the last month. This hints that sentiment is positive but still a bit cautious. Recent headlines have focused on Thermo Fisher’s steady deal making in life...
  Dec 10, 2025
• Synopsys upgraded, Warner Bros. downgraded: Wall Street’s top analyst calls
  The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential Top 5 Upgrades: Rosenblatt upgr
  Dec 10, 2025
• Goldman Sachs starts Life Sciences Tools coverage, rates these 3 stocks at Buy
  Investing.com -- Goldman Sachs has launched coverage of the Life Sciences Tools sector with a selective stance, arguing that the group should ultimately “return to their historic market growth rate of ~5%,” but only as certain end markets recover faster than others.
  Dec 9, 2025
• DNA Diagnostics Market Projected to Surge by 66% to USD 21.69 Billion by 2030
  The DNA Diagnostics Market is set to surge from USD 13.07 billion in 2024 to USD 21.69 billion by 2030, growing at a CAGR of 8.81%. Key trends driving this growth include the emergence of liquid biopsies, the rise of direct-to-consumer testing, the shift to smart bioinformatics, and advancements in genomics and personalized medicine. Increasing genetic disorder prevalence, improved DNA sequencing technology, and expanded diagnostic applications further fuel market expansion. North America leads
  Dec 9, 2025
• Synopsys upgraded, Warner Bros. downgraded: Wall Street's top analyst calls
  Synopsys upgraded, Warner Bros. downgraded: Wall Street's top analyst calls
  Dec 9, 2025
• Beat the Market the Zacks Way: Veracyte, Las Vegas Sands, 3M in Focus
  Veracyte, Las Vegas Sands and 3M shine as Zacks spotlights standout stock gains and portfolio wins amid shifting market sentiment.
  Dec 8, 2025
• Patient Engagement in Genomics Research Fuels Growth in Healthcare Segment
  The global genomics market is set to expand from USD 47.07 billion in 2025 to USD 85.09 billion by 2030, with a CAGR of 12.6%. Driven by increased government funding, rising disease prevalence, and advances in NGS technologies, the market sees augmented application in healthcare, agriculture, and forensics. The reagents, kits, and consumables segment is projected with the highest growth, fueled by ongoing genomic experiments. Key players like Illumina and Thermo Fisher Scientific are pivotal, es
  Dec 8, 2025
• Thermo Fisher’s New Asia Bioprocessing Network Might Change The Case For Investing In Thermo Fisher Scientific (TMO)
  In late 2025, Thermo Fisher Scientific expanded its bioprocessing footprint across Asia, opening a new Bioprocess Design Center in Hyderabad, India and enlarging existing hubs in Incheon, Korea and Singapore to support faster, more efficient and sustainable biologics manufacturing. This tri-hub network creates a tightly connected regional platform that gives biopharma customers local access to advanced technologies, process design expertise and training, potentially deepening Thermo Fisher’s...
  Dec 5, 2025
• Why Is Waters (WAT) Up 6.9% Since Last Earnings Report?
  Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 4, 2025
• What Made Thermo Fisher Scientific (TMO) a Solid Performer in Q3?
  Harding Loevner, an asset management company, released its “Global Equity Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.62% gross (2.52% net) in the third quarter of 2025, compared to a 7.74% return for the MSCI All Country World Index and 7.36% gain for the MSCI […]
  Dec 4, 2025
• Why Is Hologic (HOLX) Up 1% Since Last Earnings Report?
  Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 3, 2025
• TMO Stock Benefits From New Bioprocess Design Center in Asia
  Thermo Fisher expands its Bioprocess Design Centers across Asia, boosting biomanufacturing speed, efficiency and regional innovation.
  Dec 3, 2025
• Thermo Fisher (TMO) Raises €2.1 Billion Through Floating and Fixed-Rate Senior Notes
  Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the best dividend stocks to buy according to hedge funds. On November 25, Thermo Fisher reported that it had made an offering of euro-dominated notes in the principal amount of €2.1 billion. The notes are planned to be issued via Thermo Fisher Scientific (Finance I) B.V., the […]
  Dec 2, 2025
• Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers
  WALTHAM, Mass., December 02, 2025--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desi
  Dec 2, 2025
• Buffer Preparation Market Trends & Forecasts Report 2025-2035 Featuring Asahi Kasei, Avantor, Canvax, Danaher, GE, HOPAX, Merck, Prepared Biologics, Sartorius, Sepragen, Thermo Fisher Scientific, ZETA
  Key opportunities in the buffer preparation market include expanding demand for advanced buffer systems in biopharma production, increasing preference for outsourcing to reduce costs, and growth potential in reusable equipment and liquid formulations. North America remains dominant, while Asia-Pacific exhibits high growth potential. Scale of Operation Scale of Operation Buffer Service Providers Buffer Service Providers Buffer Manufacturing Systems Buffer Manufacturing Systems Dublin, Dec. 01, 20
  Dec 1, 2025
• A Look At The Intrinsic Value Of Thermo Fisher Scientific Inc. (NYSE:TMO)
  Key Insights The projected fair value for Thermo Fisher Scientific is US$603 based on 2 Stage Free Cash Flow to Equity...
  Nov 29, 2025
• North America Mass Spectrometry Market Report 2025-2033, Profiles of Agilent Technologies, Bruker, Danaher, Hitachi, JEOL, LECO, PerkinElmer, and Thermo Fisher Scientific
  The North America Mass Spectrometry Market is poised to surge from US$ 2.6 Billion in 2024 to US$ 4.87 Billion by 2033, driven by a 7.21% CAGR. Key growth areas include pharmaceutical, environmental analysis, and food safety sectors, powered by advancements in mass spectrometry technology enhancing sensitivity and precision. Major drivers include increased demand in the pharmaceutical and biotechnology sectors, advancements in hybrid and high-resolution technologies, and growing applications in
  Nov 28, 2025
• US STD Diagnostics Market Forecast and Company Analysis 2025-2033 Featuring Abbott, F. Hoffmann-La Roche, Hologic, BD and Co, Danaher, Siemens, bioMerieux, Thermo Fisher Scientific, Qiagen, Bio-Rad
  The United States STD Diagnostics Market is set to grow from US$ 5.06 billion in 2024 to US$ 8.49 billion by 2033, achieving a CAGR of 5.91% from 2025 to 2033. Key growth drivers include rising STD prevalence, technological advancements, increased awareness, and supportive government initiatives. Rapid point-of-care tests and molecular diagnostics are gaining traction, while high costs and regulatory hurdles persist as challenges. Major markets like California, Texas, New York, and Florida lead
  Nov 26, 2025
• Thermo Fisher Scientific Stock: Is TMO Outperforming the Health Care Sector?
  Thermo Fisher Scientific has outperformed the broader healthcare sector over the past year, and analysts continue to hold a strongly bullish view on its growth prospects.
  Nov 26, 2025
• Are Thermo Fisher Shares a Fair Deal After Key Pharma Partnerships and 14% Price Surge?
  Ever wondered if Thermo Fisher Scientific's stock is truly worth its current price? Let's dive into what those numbers may be telling us. The share price has climbed an impressive 14.4% over the past year, with a 12.2% gain so far in 2024. This signals growing investor confidence and possible changes in how the market perceives the company's risks and rewards. Recently, Thermo Fisher has been in the spotlight after expanding partnerships with major pharmaceutical players and making...
  Nov 25, 2025
• Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes
  WALTHAM, Mass., November 25, 2025--Thermo Fisher Scientific Inc. (NYSE: TMO) ("Thermo Fisher") announced today that it has priced an offering of €2.1 billion aggregate principal amount (the "Offering") of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary:
  Nov 25, 2025
• 1 Cash-Producing Stock to Own for Decades and 2 Facing Headwinds
  While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
  Nov 24, 2025
• Beat the Market the Zacks Way: Goldman Sachs, Micron, Prelude in Focus
  GS stands out as Zacks showcases how its stock picks like MU and PRLD delivered strong gains despite a shaky market.
  Nov 24, 2025
• Net Lease Office Properties Declares Special Cash Distribution of $4.10 Per Share
  Net Lease Office Properties (NYSE: NLOP) reported today that its Board of Trustees declared a special cash distribution of $4.10 per common share, totaling approximately $60.7 million. The distribution is payable on December 19, 2025 to shareholders of record as of the close of business on December 4, 2025.
  Nov 24, 2025
• Liquid Biopsy Market Competitive Landscape Report 2025: Recent Developments, Strategies, Sustainability Benchmarking, Product Analysis, Key Persons and Revenue
  The Liquid Biopsy market is projected to grow robustly from US$ 4.29 Billion in 2024 to US$ 15.46 Billion by 2033, driven by advancements in oncology and precision medicine. This sector benefits from the minimally invasive nature of liquid biopsies, which allow early cancer detection and treatment monitoring through blood samples. Key players like Roche, Exact Sciences, and Thermo Fisher are enhancing their offerings to meet the rising demand. Innovations and regulatory approvals continue to exp
  Nov 24, 2025
• Why Is Thermo Fisher (TMO) Up 0.2% Since Last Earnings Report?
  Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Nov 21, 2025
• Solventum inks $725M Acera takeover
  The company has stepped up its interest in M&A since making a $4.1 billion divestiture that strengthened its balance sheet.
  Nov 21, 2025
• TMO Stock May Rise Post New PCR Test in Collab With Coca-Cola Partner
  Thermo Fisher's new all-in-one SureTect qPCR assay promises faster, broader beverage spoilage detection and sharper quality control.
  Nov 20, 2025
• The Bull Case For Thermo Fisher Scientific (TMO) Could Change Following EXENT System Clearance and New Philly Center Opening – Learn Why
  Thermo Fisher Scientific recently received U.S. 510(k) clearance for its EXENT System, an automated analyser aimed at improving the diagnosis of multiple myeloma, and announced the grand opening of its East Coast Advanced Therapies Collaboration Center in Philadelphia to support cell and gene therapy innovation. These milestones expand Thermo Fisher's expertise in diagnostics and advanced therapies, providing researchers and clinicians with new tools and infrastructure to accelerate...
  Nov 20, 2025
• Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer
  CARLSBAD, Calif., November 20, 2025--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors w
  Nov 20, 2025
• Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth
  BILLERICA, Mass., November 20, 2025--Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company’s next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company’s Board
  Nov 20, 2025
• OutSystems Agent Workbench Accelerates Enterprise Agentic AI Adoption
  OutSystems, the leading AI-powered low-code development platform, today announced strong early momentum for Agent Workbench, its enterprise-grade platform for building and orchestrating intelligent AI agents across data sets, workflows, or systems. Following its general availability launch on September 30, enterprises across industries are already using Agent Workbench to accelerate agentic transformation, moving from pilots to production and orchestrating multi-agent workflows with built-in hum
  Nov 20, 2025
• Thermo Fisher Scientific Launches Industry-First, Multi-Parameter Molecular Assay for Rapid Beverage Quality Testing*
  WALTHAM, Mass., November 19, 2025--To support the quality of beverage products, Thermo Fisher Scientific today introduced the Thermo Scientific™ SureTect™ Beverage Spoilage Multiplex qPCR Assay**, an industry-first all-in-one quantitative Polymerase Chain Reaction (PCR)-based test developed in collaboration with Coca-Cola Europacific Partners. Now part of the Thermo Scientific SureTect PCR System, the assay offers early and accurate detection of spoilage organisms earlier in the production proce
  Nov 19, 2025
• Institutions Love These 3 Companies, Should You As Well?
  Retail investors seeking companies vetted by professionals might look to these three companies, all of which are heavily owned by institutional investors.
  Nov 19, 2025
• Real-time data: how to gain an edge amid clinical services consolidation
  Amanda Murphy, senior director at GlobalData shares how companies can ensure success amidst consolidation in the clinical services sector.
  Nov 18, 2025
• These 3 Stocks Are Using Buybacks to Signal Market Confidence
  Buybacks are getting a boost at three $20B to $200B firms. Does Trade Desk's repurchase authorization signal confidence, or is it too early to tell?
  Nov 18, 2025
• Thermo Fisher Scientific Launches CorEvitas Clinical Registry in Myasthenia Gravis, a Rare Autoimmune Disorder
  WALTHAM, Mass., November 17, 2025--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the enrollment of the first patient in the new PPD™ CorEvitas™ Myasthenia Gravis (MG) Registry. This nationwide registry will collect data from MG patients across the United States to study and evaluate existing and emerging MG therapies, tracking health conditions, safety issues, medication usage and overall treatment effectiveness. By leveraging real-world data, the registry w
  Nov 17, 2025
• The Zacks Analyst Blog Highlights NVIDIA, Micron Technology and Thermo Fisher Scientific
  Zacks spotlights NVIDIA, Micron and Thermo Fisher in its latest Analyst Blog, highlighting AI-driven tailwinds, memory-market momentum and ongoing innovation across life sciences.
  Nov 14, 2025
• If You Invested $1000 in Thermo Fisher Scientific 10 Years Ago, This Is How Much You'd Have Now
  Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
  Nov 14, 2025
• Thermo Fisher Scientific (TMO): Assessing Valuation After a 10% Monthly Share Price Surge
  Thermo Fisher Scientific (TMO) has caught investors’ attention lately as its shares climbed more than 10% over the past month. The company’s strong recent momentum has some market watchers reassessing its long-term prospects. See our latest analysis for Thermo Fisher Scientific. After a period of sluggishness earlier this year, Thermo Fisher Scientific's 10% share price surge over the past month stands out. This supports a positive year-to-date gain and helps lift its one-year total...
  Nov 14, 2025
• Recombinant Human Fibroblast Growth Factor Global Market Forecast 2025-2030: Markets Benefit from Strategic Investments and Collaborations
  Recombinant human fibroblast growth factors offer growth prospects in regenerative medicine and cosmetics, driven by efficient production systems. Key opportunities arise from applications in wound healing, tissue engineering, and cosmetics. Notable firms include Thermo Fisher and Merck.Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The "Recombinant Human Fibroblast Growth Factor Market - Global Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering. Recombinant human fibrobla
  Nov 14, 2025
• Thermo Fisher Scientific Digital Transformation Strategy Analysis Report 2025: Digital Transformation and Innovation Strategy, Technology Initiatives, Investments, and Acquisitions
  Thermo Fisher presents market opportunities through digital transformation, innovation programs, and strategic tech initiatives. They leverage partnerships, product launches, and acquisitions across segments like Life Sciences, Analytical Instruments, and Diagnostics, aiding pharmaceuticals, research, and healthcare sectors.Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: Thermo Fisher Scientific - 2025" company profile has been added to ResearchAndMarkets.com's o
  Nov 14, 2025
• Devyser Diagnostics AB (FRA:OL0) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ...
  Devyser Diagnostics AB (FRA:OL0) reports a 20% sales growth and strong cash position, while navigating distributor sales decline and profitability hurdles.
  Nov 13, 2025
• Top Research Reports for NVIDIA, Micron Technology & Thermo Fisher
  NVIDIA, Micron Technology and Thermo Fisher lead today's top analyst picks, each showing strong growth trends and strategic advances.
  Nov 13, 2025
• Hologic Expands European Reach of Genius Digital Diagnostics System
  HOLX gains expanded CE marking for its Genius Digital Diagnostics System, enabling imaging of both cell and tissue specimens on one platform.
  Nov 13, 2025
• Are Wall Street Analysts Predicting Thermo Fisher Scientific Stock Will Climb or Sink?
  Thermo Fisher Scientific has underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.
  Nov 13, 2025
• Thermo Fisher Scientific Receives 510(k) Clearance in the United States for EXENT System* to Aid in the Diagnosis of Multiple Myeloma
  WALTHAM, Mass., November 12, 2025--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced 510(k) clearance of the EXENT® Analyser and Immunoglobulin Isotypes (GAM) Assay**, a first-of-its-kind automated platform for clinical laboratories. The EXENT System combines enhanced sensitivity and automation to provide accurate results, helping clinicians make a fast diagnosis for patients with multiple myeloma and related disorders.
  Nov 12, 2025
• Enterprises Are Adopting Data and Governance Frameworks and Talent Strategies for Agentic AI, ISG Says
  STAMFORD, Conn., November 12, 2025--Enterprise leaders will join the ISG AI Impact Summit, November 17–18 in New York, to discuss adopting, scaling and governing AI business solutions.
  Nov 12, 2025
• Beat the Market the Zacks Way: Amgen, Ciena, Fair Isaac in Focus
  Amgen, Ciena, and Fair Isaac shine as Zacks' proven stock-ranking strategies continue to outperform amid market uncertainty.
  Nov 10, 2025
• Implied Volatility Surging for Thermo Fisher Stock Options
  Investors need to pay close attention to TMO stock based on the movements in the options market lately.
  Nov 10, 2025
• Thermo Fisher Unveils $5 Billion Buyback, Keeps Dividend Intact
  The life sciences giant signals confidence with a massive repurchase plan and steady shareholder payouts
  Nov 7, 2025
• Thermo Fisher Scientific Inc.'s (NYSE:TMO) Stock Is Going Strong: Have Financials A Role To Play?
  Thermo Fisher Scientific (NYSE:TMO) has had a great run on the share market with its stock up by a significant 23% over...
  Nov 7, 2025
• Diamond Hill Capital Large Cap Fund Added Thermo Fisher Scientific (TMO) on a Dip
  Diamond Hill Capital, an investment management company, released its “Large Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Markets continued their YTD rally in the third quarter of 2025, with the Russell 3000 Index gaining 8%, bringing the calendar-year returns to over 14%. The portfolio declined and underperformed the […]
  Nov 6, 2025
• Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases
  WALTHAM, Mass., November 06, 2025--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has authorized the repurchase of $5 billion of shares of its common stock in the open market or in negotiated transactions. The authorization has no expiration date.
  Nov 6, 2025
• Thermo Fisher Scientific Declares Quarterly Dividend
  WALTHAM, Mass., November 06, 2025--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.43 per common share, payable on January 15, 2026, to shareholders of record as of December 15, 2025.
  Nov 6, 2025
• Cas12 Protein Market Report 2025: Market Led by Thermo Fisher, Bio-Techne and IDT, With APAC Set for Fastest Growth Despite Trade-Driven Supply Challenges - Global Forecast to 2029 and 2034
  Key market opportunities for Cas12 proteins include rising government investments in biotech, increased demand for diagnostics in developing regions, growing integration into sequencing platforms, gene-editing advancements, and expanding applications in personalized medicine and agricultural biotechnology. Cas12 Protein Market Cas12 Protein Market Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The "Cas12 Protein Market Report 2025" has been added to ResearchAndMarkets.com's offering. The Cas12 Protei
  Nov 4, 2025
• Methyl Acetate Industry Research and Global Forecast Report 2025-2030: Lucrative Opportunities in Expanding Applications Across High-Growth Industries, & Growth Through Bio-based and Circular Economy
  The global methyl acetate market is projected to grow from USD 228.0 million in 2025 to USD 388.5 million by 2030, at a CAGR of 7.9%. This growth is driven by its fast-evaporating, low-toxicity advantages, making it a preferred solvent in paints, coatings, adhesives, pharmaceuticals, and electronics. With increasing VOC regulations from environmental bodies like the EPA and ECHA, manufacturers are innovating by offering sustainable, high-purity variants. Asia Pacific leads the market, supported
  Nov 4, 2025

TMO Reviews

• HODLWarrior

  Dec 30, 2025

  $TMO Dominating the lab scene, their tech game is on fire!

  Buy

• PortfolioGremlin

  Dec 30, 2025

  $TMO When it comes to science, this outfit is flexin’ hard, no doubt!

  Buy

• PortfolioPunk

  Dec 29, 2025

  $TMO Leading the pack in overpriced lab equipment.

  Sell

• StonkPhantom

  Dec 28, 2025

  $TMO In the race against time for scientific breakthroughs, every second counts. Will this giant maintain its lead or find itself in a tight spot with competition breathing down its neck?

  Buy

• BagholderPrime

  Dec 27, 2025

  $TMO Investing here is like finding a golden ticket in your chocolate bar—who doesn’t love a sweet surprise in science?

  Buy

• AlphaRogue

  Dec 27, 2025

  $TMO This company is like the nerdy kid in science class who actually gets to blow things up—using science for better health, of course!

  Buy

• StonkDestroyer

  Dec 26, 2025

  $TMO If only their performance matched their price tag.

  Sell

• VolatilityNomad

  Dec 26, 2025

  $TMO This company is as exciting as a lab coat.

  Sell

• MarketDrift

  Dec 25, 2025

  $TMO Top-tier science flow, keepin' the health game strong!

  Buy

• CashWraith

  Dec 25, 2025

  $TMO In the race for cutting-edge scientific solutions, every second counts! Will they lead the charge or get lost in the crowd of innovators? The clock is ticking!

  Buy

• BagholderPrime

  Dec 24, 2025

  $TMO This company is the science nerd everyone wants in their study group—always bringing the coolest experiments to the table!

  Buy

• CodeAndCapital

  Dec 24, 2025

  $TMO This company is like a science project gone right—lots of potential and hopefully no explosions!

  Buy

• BearBreaker

  Dec 24, 2025

  $TMO A bit too comfortable in their monopolistic bubble.

  Sell

• TradeGoblin

  Dec 23, 2025

  $TMO Science is the future, and this one's pushing the limits!

  Buy

• DividendHunter

  Dec 22, 2025

  $TMO Sure, they're in science, but their stock is pure fiction.

  Sell

• BullishShade

  Dec 22, 2025

  $TMO With ongoing advancements in life sciences and diagnostics, this company's broad product range plays a critical role in healthcare. Their commitment to research and development may drive future innovation and market leadership.

  Buy

• BearishBoi

  Dec 22, 2025

  $TMO If this stock were a science experiment, it would definitely get an A+ for its stellar results and cool gadgets!

  Buy

• CashKiller

  Dec 22, 2025

  $TMO Cashing in on science while everyone else is just guessing.

  Buy

• CapitalCrusher

  Dec 21, 2025

  $TMO Think of this one as the overachiever in school who gets straight A's and still manages to be cool. Total vibe!

  Buy

• BullishCraze

  Dec 21, 2025

  $TMO This corporation continues to lead in the life sciences sector, offering cutting-edge solutions that cater to a variety of scientific needs. Their consistent performance and dedication to innovation may attract considerable attention from industry stakeholders.

  Buy

• YOLOTrader

  Dec 21, 2025

  $TMO This company does science like it's a magic show! Watch closely—it's hard to believe how they pull off those profits!

  Buy

• BullishBard

  Dec 20, 2025

  $TMO Like the ultimate science nerd, this company makes lab gear that could make even your grandma feel like a mad scientist!

  Buy

• OptionCipher

  Dec 20, 2025

  $TMO As advancements in science accelerate, staying ahead of the curve is essential for this giant. The pressure to innovate is immense, and any delays could shake investor confidence to its core.

  Sell

• TradingNomad

  Dec 20, 2025

  $TMO The race for medical advancements never stops, yet competition is fierce! Can they keep innovating without burning out, or will they struggle to keep up?

  Buy

• VolatilityNomad

  Dec 18, 2025

  $TMO Leading the pack? More like just keeping pace.

  Sell

• BullishSniper

  Dec 18, 2025

  $TMO Running the science game like a boss, this company turns labs into playgrounds where genius takes center stage—who knew testing could be so cool?

  Buy

• OptionOverlord

  Dec 18, 2025

  $TMO They’re the wizards of the lab—making magic happen while we sit here like muggles!

  Sell

• EarningsEcho

  Dec 18, 2025

  $TMO This firm is like the ultimate lab partner, always ready with the coolest science gadgets. Can they help me with my chemistry homework too?

  Buy

• ProfitVortex

  Dec 17, 2025

  $TMO They're on a mission to make science cooler than my last birthday party!

  Buy

• FinTechFrost

  Dec 16, 2025

  $TMO This company is like a science wizard—turning test tubes into gold! Just don't ask them to do your science homework.

  Buy

• BullRunBoi

  Dec 16, 2025

  $TMO When it comes to science, these folks are straight-up magicians!

  Buy

• ChartNomad

  Dec 15, 2025

  $TMO Bears taking control of the chart.

  Sell

• TheAlphaDagger

  Dec 14, 2025

  $TMO In the world of biotech and health, every new discovery can change the game overnight. The anticipation is electric, but so are the risks! Will the latest innovations hit the mark, or are we in for a letdown? It’s nerve-wracking!

  Sell

• ChartPilot

  Dec 14, 2025

  $TMO This one has such a strong grip on the biotech scene, but can it maintain its edge amidst fierce competition? It's a rollercoaster of emotions with every news release—hold on tight!

  Buy

• StonkSlayer

  Dec 13, 2025

  $TMO This stock is basically the science nerd everyone loved in high school—always coming up with cool stuff that makes life easier!

  Buy

• BullishBerserker

  Dec 13, 2025

  $TMO Scientific advancements are racing forward, but will this company keep pace or be left behind? The pressure to innovate is immense right now!

  Buy

• BullishMyth

  Dec 13, 2025

  $TMO Downside expansion possible soon.

  Sell

• ProfitVandal

  Dec 12, 2025

  $TMO Success is fleeting; keep waiting for the other shoe to drop.

  Sell

• BullishShade

  Dec 12, 2025

  $TMO Bearish weight too strong.

  Sell

• PnLReaper

  Dec 12, 2025

  $TMO This company stands at the forefront of scientific innovation, contributing to advancements in health and life sciences. Its commitment to research and development is likely to yield breakthroughs that enhance its competitive edge.

  Buy

• TradeHex

  Dec 12, 2025

  $TMO Momentum shift undeniable.

  Buy

• CashClown

  Dec 12, 2025

  $TMO All signs point downward.

  Sell

• TickerTrickster

  Dec 11, 2025

  $TMO Technical setup suggests upward expansion.

  Buy

• CodeTrader

  Dec 11, 2025

  $TMO Bearish dominance undeniable.

  Sell

• TradePhantom

  Dec 10, 2025

  $TMO Like a diamond in the rough, except it’s just rough.

  Sell

• TheAlphaDagger

  Dec 10, 2025

  $TMO In the ever-evolving world of biotech, this powerhouse is racing against time to maintain its lead. Market rumors are swirling—what's the next big breakthrough or setback?

  Buy

• TradePulse

  Dec 9, 2025

  $TMO Watching this stock is like being at a high-stakes poker table; every movement is crucial, and the pressure keeps mounting. You’re on edge, waiting for the next big play!

  Buy

• BullishSniper

  Dec 9, 2025

  $TMO Science is their jam, and they’re rocking it harder than a high school band at a pep rally!

  Buy

• ProfitFang

  Dec 9, 2025

  $TMO As a major player in the scientific research and laboratory equipment sector, this company’s broad range of products and services caters to critical markets. Its commitment to innovation and quality underpins its strong market position.

  Buy

• DigitalDividend

  Dec 9, 2025

  $TMO With science on its side, this stock makes you feel like a genius just for knowing it exists!

  Buy

• QuantAssault

  Dec 9, 2025

  $TMO Sharp bearish shift underway.

  Sell

• VolatilityNomad

  Dec 8, 2025

  $TMO Like getting a root canal, but without the anesthesia.

  Sell

• QuantSpecter

  Dec 8, 2025

  $TMO In the world of scientific innovation, this giant has a weighty reputation to uphold. The question is, can they keep pushing boundaries without stumbling?

  Buy

• TheQuantEdge

  Dec 8, 2025

  $TMO In a world of rapid scientific advancement, this company's ability to innovate is paramount. Can they keep pace and drive growth, or will they be eclipsed by competitors?

  Buy

• CapitalCarnage

  Dec 8, 2025

  $TMO So overpriced, even science can’t justify it.

  Sell

• TickerTakedown

  Dec 8, 2025

  $TMO This company is like a science lab on steroids—seriously impressive results every time!

  Buy

• RiskWraith

  Dec 7, 2025

  $TMO In a world where scientific innovation is a race against time, will they secure their spot at the front, or risk being left behind? The stakes could not be higher!

  Buy

• DividendVandal

  Dec 7, 2025

  $TMO This global leader in scientific solutions is continually advancing in the biopharmaceutical space. Their innovative technologies drive efficiency and precision, making them a key player in improving healthcare outcomes.

  Buy

• MarginMarauder

  Dec 7, 2025

  $TMO Science nerds rejoice! They’re the mad scientists making cool lab stuff that actually saves lives—how awesome is that?

  Buy

• ProfitFang

  Dec 7, 2025

  $TMO This company continues to lead in the life sciences sector, driving innovation in analytical instruments and diagnostic solutions. Its diverse product offerings and emphasis on research development present a solid foundation for growth.

  Buy

• ShortSavage

  Dec 6, 2025

  $TMO A critical player in a life-saving industry, but are they agile enough to adapt to rapid changes? Every breakthrough could be a double-edged sword!

  Buy

• FiscalEngine

  Dec 6, 2025

  $TMO This leader in the life sciences industry is continuously pushing the boundaries of innovation through its diverse offerings in laboratory equipment and services. Its commitment to scientific advancement underlines its pivotal role in healthcare.

  Buy

• YieldSlasher

  Dec 6, 2025

  $TMO Innovation? More like a snoozefest in lab coats.

  Sell

• StonkSlayer

  Dec 5, 2025

  $TMO Like the kid in class who gets all the answers right—definitely the teacher's pet of the stocks!

  Buy

• ShortSniper

  Dec 4, 2025

  $TMO Innovation? More like tired old tricks in a lab coat.

  Sell

• CapitalCrusher

  Dec 4, 2025

  $TMO Momentum deeply negative.

  Sell

• RiskDriver

  Dec 4, 2025

  $TMO Renowned for its cutting-edge technologies and contributions to healthcare, this organization is at the forefront of scientific advancement, making significant impacts that could influence market dynamics.

  Buy

• CashWraith

  Dec 4, 2025

  $TMO Big breakdown likely incoming.

  Sell

• WallStreetWraith

  Dec 3, 2025

  $TMO Healthcare innovation, if only they could innovate their stock performance.

  Sell

• QuantQuest

  Dec 3, 2025

  $TMO If this stock were a science experiment, it’d be the one that actually works — no exploding beakers here!

  Buy

• GainVector

  Dec 2, 2025

  $TMO A leader in scientific instrumentation and laboratory services, this organization is committed to advancing health and technology. Their robust product offerings and comprehensive solutions place them in a prime position within the healthcare sector.

  Buy

• AlgoAce

  Dec 1, 2025

  $TMO In the lab like a boss! If finding cures were a video game, they’d be at level 99 with a full health bar!

  Buy

• TrendStalker

  Dec 1, 2025

  $TMO Sure, if you love overpriced lab equipment.

  Sell

• TradeTracer

  Dec 1, 2025

  $TMO This powerhouse in scientific research and diagnostics plays a pivotal role in advancing healthcare solutions. Their continuous investment in innovation is likely to drive long-term growth and improve healthcare outcomes.

  Buy

• CryptoCoyote

  Nov 30, 2025

  $TMO With the medical technology field booming, there's immense pressure to innovate faster than competitors. Will this giant rise to the occasion or falter?

  Buy

• TheGainReaper

  Nov 30, 2025

  $TMO This might be the only thing keeping the lab alive; still, it's a stretch.

  Sell

• MarginMythic

  Nov 30, 2025

  $TMO With their constant innovation and expansion into new markets, the pressure is high to keep up. Will their latest breakthroughs push them ahead or create unforeseen challenges?

  Buy

• BullishCraze

  Nov 30, 2025

  $TMO This organization is a key player in the life sciences sector, leveraging cutting-edge technologies to drive advancements in healthcare. Its continuous innovation and broad product offerings could be pivotal in addressing global health challenges.

  Buy

• ChartCrusher

  Nov 30, 2025

  $TMO Overhyped and underdelivering, as usual.

  Sell

• PnLPhantom

  Nov 29, 2025

  $TMO The promise of innovation is exciting, but the pressure is overwhelming! Every update feels monumental, and keeping up with this stock could turn your hair gray!

  Buy

• LazyQuant

  Nov 29, 2025

  $TMO This stock is like a science fair project that actually works—surprisingly impressive and might just win first place!

  Buy

• QuantSpecter

  Nov 29, 2025

  $TMO With constant innovation and a relentless push for excellence, this stock keeps everyone on their toes. The pressure is palpable, and the stakes are only getting higher.

  Buy

• HedgeKnight

  Nov 28, 2025

  $TMO If science had a prom king, this would be it—always winning the popularity contest with those lab coats!

  Buy

• WallStreetWolf

  Nov 28, 2025

  $TMO This one’s like a lab coat superhero—saving lives and making science cooler than your last TikTok dance!

  Buy

• ProfitVortex

  Nov 28, 2025

  $TMO This company is like the science geek in school who also aces gym class—smart, strong, and doing all the right things!

  Buy

• BullishBerserker

  Nov 28, 2025

  $TMO With the ongoing demand for healthcare solutions, this company is at a crucial crossroads. While the potential is immense, so too is the pressure to deliver results amidst increasing competition.

  Buy

• YieldSlasher

  Nov 28, 2025

  $TMO The only thing thriving here is the delusion.

  Sell

• TradeProtocol

  Nov 27, 2025

  $TMO This stock is like a lab coat—always in style and ready to dissect the competition!

  Buy

• RiskRanger

  Nov 27, 2025

  $TMO This stock is like a science fair project that actually worked—who knew lab coats could lead to profits?

  Buy

• WallStreetHex

  Nov 27, 2025

  $TMO This company plays a crucial role in advancing scientific discovery and healthcare solutions. Their ongoing commitment to innovation in life sciences reflects strong potential for continued success.

  Buy

• DividendGhost

  Nov 27, 2025

  $TMO Innovation in healthcare is a double-edged sword! Can they keep pace with rapid advancements and maintain a steady growth trajectory in this cutthroat environment?

  Buy

• OptionShadow

  Nov 26, 2025

  $TMO A leader in the life sciences sector, this company is consistently at the forefront of innovation, providing cutting-edge solutions that drive scientific discovery and improve healthcare outcomes.

  Buy

• TradeMatrix

  Nov 25, 2025

  $TMO In the fast-paced world of biotechnology, every breakthrough is a race against time. The pressure to deliver results is immense, and the stakes have never been higher!

  Buy

• CapitalCrusher

  Nov 25, 2025

  $TMO This stock is like the kid in class who can ace tests without studying. Super smart choice!

  Buy

• CapitalHex

  Nov 24, 2025

  $TMO This company is at the forefront of scientific innovation, offering cutting-edge solutions that are essential in various research and clinical settings. With a strong commitment to excellence and a diverse portfolio, it continues to enhance its market position.

  Buy

• DividendVortex

  Nov 24, 2025

  $TMO As a leader in scientific innovation, this company is at the forefront of advancements in healthcare technology. Their extensive research and development efforts are crucial in driving improvements across various sectors of the healthcare system.

  Buy

• CapitalFrame

  Nov 23, 2025

  $TMO This organization is a leader in providing cutting-edge solutions in the life sciences space, highlighting a commitment to advancing healthcare. Its investment in research and development showcases a forward-thinking mindset that could yield substantial returns.

  Buy

• ShortSavior

  Nov 23, 2025

  $TMO Just another overpriced company pretending to be innovative.

  Sell

• MarketMyth

  Nov 23, 2025

  $TMO A leader in the healthcare sector, this organization is committed to advancing scientific innovation. Its cutting-edge technology and comprehensive solutions are positioned to drive growth in an ever-evolving market, addressing critical health needs globally.

  Buy

• CapitalVortex

  Nov 23, 2025

  $TMO With the world relying more on advanced science, every breakthrough feels like a tightrope walk! The pressure is on to deliver, but can they keep up with the relentless demand for innovation?

  Buy

• DiamondHandz

  Nov 21, 2025

  $TMO Science game strong, cooking up breakthroughs like it’s nobody's business!

  Buy

• BuyLowBro

  Nov 21, 2025

  $TMO They’ve got the right tools to keep things running, kinda like the dad who always has duct tape and a toolbox ready.

  Buy

• TradePulse

  Nov 21, 2025

  $TMO As the healthcare sector sways under political pressures, this giant could either thrive in the chaos or struggle to keep its footing. Hold your breath—it's a wild ride!

  Buy

• CashMeOutside

  Nov 21, 2025

  $TMO Heavy hitters in healthcare; they ain't playin' games!

  Buy

• AlphaStriker

  Nov 20, 2025

  $TMO Sure, they're in the lab, but where's the magic?

  Sell

• AlgoAce

  Nov 19, 2025

  $TMO Investing here feels like getting an A on a science project—feels good, but keep studying for those pop quizzes!

  Buy

• TradeNova

  Nov 19, 2025

  $TMO They be stackin’ up the wins, don’t sleep on this player!

  Buy

• ByteBull

  Nov 18, 2025

  $TMO The only scientist who can make lab coats look cool, proving that even in the lab, style matters as much as data!

  Buy

• CashClown

  Nov 17, 2025

  $TMO Big science vibes, always in the lab cookin' up gold.

  Buy

• PnLReaper

  Nov 17, 2025

  $TMO With a comprehensive range of scientific instruments and reagents, this company is integral to advancing healthcare and research. Its innovation-driven approach is likely to sustain its leadership in the industry.

  Buy

• AlphaRift

  Nov 17, 2025

  $TMO As a leader in scientific instrumentation and diagnostics, this corporation consistently sets benchmarks in quality and innovation. Its diverse portfolio positions it favorably within the healthcare and life sciences markets.

  Buy

• RiskProtocol

  Nov 17, 2025

  $TMO Innovation and growth are relentless in the biotech world, but can this player keep pace with the skyrocketing demands for healthcare solutions? Every move feels like a high-stakes gamble!

  Buy

• CashCombo

  Nov 16, 2025

  $TMO This stock is like that friend who's super into science—always doing experiments and making amazing breakthroughs, but can be a bit nerdy!

  Buy

• GammaSlayer

  Nov 16, 2025

  $TMO Great tech, but is it sticking around?

  Sell

• TheQuantEdge

  Nov 15, 2025

  $TMO With health trends shifting rapidly, can this company adapt and thrive, or will it buckle under the weight of expectations? The heat is on!

  Sell

• RiskReaper

  Nov 15, 2025

  $TMO This company continues to innovate in the life sciences sector, bringing cutting-edge solutions to the market that enhance research and clinical diagnostics. Their commitment to quality and advancement positions them well for future growth.

  Buy

• TheAlphaDagger

  Nov 15, 2025

  $TMO This leader in scientific innovation is under pressure to maintain its edge, and market dynamics are relentless. Will it continue to thrive or falter under scrutiny?

  Sell

• TrendStalker

  Nov 14, 2025

  $TMO A giant in a sea of mediocrity, but still overrated.

  Sell

• CapitalCarnage

  Nov 14, 2025

  $TMO Solid tech, but don't kid yourself—it's not a miracle worker.

  Sell

• GammaSlayer

  Nov 14, 2025

  $TMO Sure, they’re big, but are they really innovative anymore?

  Sell

• PortfolioFreak

  Nov 14, 2025

  $TMO In a world where health is paramount, this scientific powerhouse is pivotal, but any slip could jeopardize their standing, creating a whirlwind of anxiety for stakeholders.

  Buy

• SignalStriker

  Nov 13, 2025

  $TMO In the biotech arena, stakes couldn't be higher. With innovations and competitors nipping at their heels, will they secure their place at the top or fall behind? The tension is almost unbearable!

  Buy

• QuantAssault

  Nov 12, 2025

  $TMO They might not be magicians, but this company sure knows how to turn science into a money-making magic show!

  Buy

• ProfitGremlin

  Nov 11, 2025

  $TMO This player’s makin' big moves, stay tuned for the show!

  Buy

• ShortSqueezeX

  Nov 11, 2025

  $TMO This one’s like the nerd in class with the coolest gadgets — always ready to experiment with new tech!

  Buy

• HODLzilla

  Nov 10, 2025

  $TMO Science squad is flexing hard, making health wins for days!

  Buy

• IndexPredator

  Nov 10, 2025

  $TMO As a leader in scientific research tools, the potential for breakthroughs is huge, but so is the competition. Can it continue to lead in innovation while fending off challengers? Tensions are high.

  Buy

• FiscalFury

  Nov 8, 2025

  $TMO This stock is the science nerd in the corner who always has the coolest gadgets—nerdy, but crucial for the cool kids!

  Buy

• StockShotz

  Nov 8, 2025

  $TMO Traders in disbelief, bulls in paradise. Even my risk management is.

  Buy

• GainsJester

  Nov 8, 2025

  $TMO Chart looks like my sleep schedule - completely broken. Bulls and bears are just trading.

  Sell

• TradePulse

  Nov 8, 2025

  $TMO With the healthcare landscape constantly evolving, this powerhouse faces an uphill battle filled with competition and innovation. Will they lead the charge or get lost in the fray?

  Buy

• BullishBard

  Nov 7, 2025

  $TMO volume tax momentum trigger levels go levels soon heavy bid tape heavy strong wild mode feels

  Buy

• VolatilityCore

  Nov 5, 2025

  $TMO hands clear levels bull soon range heavy fire clean today diamond hands patience charts passed king tight tbh today level-to-level buzzing on clean

  Buy

• AlphaRift

  Nov 3, 2025

  $TMO This chart's more unpredictable than my ex. If patience was a stock, I'd be rich by.

  Buy

• EarningsEcho

  Nov 3, 2025

  $TMO Vibes are bullish and my coffee agrees. Feels like this ticker just.

  Sell

• RiskReaper

  Oct 19, 2025

  $TMO If charts could talk, this one would say, 'Let's ride!'.

  Buy

• QuantRift

  Oct 17, 2025

  $TMO This chart's more unpredictable than my ex. Volatility got me questioning.

  Sell

• VolatilityCore

  Oct 16, 2025

  $TMO loud risk volume sentiment trigger smart go buzzing momentum eyes watching trigger tape gap noise smooth trigger maybe flows vibes hurts tax today

  Buy

• StockSpecter

  Oct 10, 2025

  $TMO Chart's climbing like it heard good news from the universe.

  Sell

• DividendVortex

  Sep 29, 2025

  $TMO If optimism were tradable, I'd be all in. Price action smoother than.

  Buy

• GainMachine

  Sep 24, 2025

  $TMO Feels like the market finally woke up on the right side of.

  Sell

• CryptoCobra

  Sep 24, 2025

  $TMO Momentum so clean I'd frame this chart. Candle after candle - this thing.

  Buy

• TheEquityEdge

  Sep 23, 2025

  $TMO every sold smells like gets instantly regret bounce

  Buy

• HoldTheLine

  Sep 23, 2025

  $TMO This chart needs therapy. Volume so low it's whispering sweet.

  Buy

• ProfitShade

  Sep 17, 2025

  $TMO Candle after candle - this thing refuses to chill. Every breakout feels like.

  Sell

• YieldSlasher

  Aug 31, 2025

  $TMO Volume so low it's whispering sweet nothings. This chart needs therapy.

  Sell

• GainSurge

  Aug 29, 2025

  $TMO vibes hurts hands sentiment clean today mode trigger gap gains spike printing clean hurts clean

  Buy

• DividendDegen

  Jul 27, 2025

  $TMO grind now grind trigger macro theta now ath noise trigger beastly run rocket tape on tape level-to-level level-to-level

  Buy

• YOLOTrader69

  Jul 13, 2025

  $TMO it on smart move diamond rocket heat soon now humming dripping soon it run energy

  Buy

• EarningsEcho

  Apr 19, 2025

  $TMO dripping imo passed passed today passed on tape macro hurts volume and

  Buy

• MarketMarauder

  Mar 28, 2025

  $TMO soon-ish nasty theta charts pumping maybe smart queued and mooning vol now bull tape it whispers and no noise

  Buy

• WallStreetVandal

  Feb 18, 2025

  $TMO go today keeping spike humming uptrend vibes diamond clean move imo tape clean level-to-level frankly uptrend here trigger momentum

  Buy

• TrendStalker

  Dec 31, 2024

  $TMO tape rocket strong ath hurts beastly vibes bid theta volume vol steady vibes

  Buy

• TradeNinja

  Nov 19, 2024

  $TMO level-to-level tape crushing imo and money whispers smooth heating heavy whoa king whoa

  Buy

• CapitalFrame

  May 8, 2024

  $TMO range doom talking hard cliff tbh spike wick bagholder ruggy noise macro vol lower whispers

  Sell

• MoneyMage

  Mar 28, 2024

  $TMO heavy macro king trend vibes clean printing king tape spike tax tight smooth

  Buy

• ShortCircuit

  Mar 25, 2024

  $TMO tbh vibes levels macro hard soon soon-ish strong talking trigger and heavy soon macro passed here loud strong tbh run

  Buy

• BearEater

  Jan 8, 2024

  $TMO alpha heavy feels tax now mode bid whoa clean hands diamond beastly no macro trigger flows trigger

  Buy

• ChartPhantom

  Dec 18, 2023

  $TMO smart feels clean now patience king diamond maybe now bounce heating wild hard gains queued momentum today tape mooning diamond

  Buy